Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives $11.25 Average Target Price from Brokerages

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have been given a consensus rating of “Buy” by the six analysts that are currently covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $11.25.

Several equities research analysts have recently commented on RVPH shares. EF Hutton Acquisition Co. I raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Monday, September 23rd. Roth Mkm initiated coverage on shares of Reviva Pharmaceuticals in a research report on Friday. They issued a “buy” rating and a $7.00 price objective for the company. Roth Capital raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Friday. Finally, Maxim Group raised shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research report on Friday.

Institutional Trading of Reviva Pharmaceuticals

An institutional investor recently raised its position in Reviva Pharmaceuticals stock. Geode Capital Management LLC boosted its position in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 278,496 shares of the company’s stock after purchasing an additional 42,376 shares during the quarter. Geode Capital Management LLC owned about 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 63.18% of the stock is currently owned by institutional investors.

Reviva Pharmaceuticals Price Performance

NASDAQ:RVPH opened at $1.91 on Friday. The firm has a 50-day moving average of $1.58 and a 200-day moving average of $1.29. The company has a market cap of $63.87 million, a PE ratio of -1.72 and a beta of -0.12. Reviva Pharmaceuticals has a one year low of $0.60 and a one year high of $4.83.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.